What delayed the lifesaving COVID-19 antiviral pill?

Published



Merck’s new antiviral pill, Molnupiravir, cuts the risk of hospitalization and death due to COVID-19 by half.

At least, that’s what a randomized clinical trial of 775 patients shows. No deaths were identified in those receiving Molnupiravir, compared with eight deaths among those receiving a placebo. Treatment was started early after initial symptom onset with an easy five-day course of twice-daily pills.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.